Analysis of genetic mutations associated with anti-malarial drug resistance in Plasmodium falciparum from the Democratic Republic of East Timor by de Almeida, Afonso et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Malaria Journal
Open Access Research
Analysis of genetic mutations associated with anti-malarial drug 
resistance in Plasmodium falciparum from the Democratic Republic 
of East Timor
Afonso de Almeida*1,2, Ana Paula Arez2, Pedro VL Cravo3 and Virgílio E do 
Rosário2
Address: 1Universidade Nacional de Timor Leste, Avenida Cidade de Lisboa, Díli, Timor Leste, 2Centro de Malária e Outras Doenças Tropicais, 
Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Rua da Junqueira 96, 1349-008 Lisboa, Portugal and 3Unidade de Biologia 
Molecular, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Rua da Junqueira 96, 1349-008 Lisboa, Portugal
Email: Afonso de Almeida* - afmeida@hotmail.com; Ana Paula Arez - aparez@ihmt.unl.pt; Pedro VL Cravo - pcravo@ihmt.unl.pt; Virgílio E do 
Rosário - virgilio.rosario@ihmt.unl.pt
* Corresponding author    
Abstract
Background: In response to chloroquine (CQ) resistance, the policy for the first-line treatment
of uncomplicated malaria in the Democratic Republic of East Timor (DRET) was changed in early
2000. The combination of sulphadoxine-pyrimethamine (SP) was then introduced for the treatment
of uncomplicated falciparum malaria.
Methods: Blood samples were collected in two different periods (2003–2004 and 2004–2005)
from individuals attending hospitals or clinics in six districts of the DRET and checked for
Plasmodium falciparum infection. 112 PCR-positive samples were inspected for genetic
polymorphisms in the pfcrt, pfmdr1, pfdhfr and pfdhps genes. Different alleles were interrogated for
potential associations that could be indicative of non-random linkage.
Results: Overall prevalence of mutations associated with resistance to CQ and SP was extremely
high. The mutant form of Pfcrt (76T) was found to be fixed even after five years of alleged CQ
removal. There was a significant increase in the prevalence of the pfdhps 437G mutation (X2 = 31.1;
p = 0.001) from the first to second survey periods. A non-random association was observed
between pfdhfr51/pfdhps437 (p = 0.001) and pfdhfr 59/pfdhps 437 (p = 0.013) alleles.
Conclusion: Persistence of CQ-resistant mutants even after supposed drug withdrawal suggests
one or all of the following: local P. falciparum may still be inadvertently exposed to the drug, that
mutant parasites are being "imported" into the country, and/or reduced genetic diversity and low
parasite transmission help maintain mutant haplotypes. The association between pfdhfr51/
pfdhps437 and pfdhfr 59/pfdhps 437 alleles indicates that these are undergoing concomitant positive
selection in the DRET.
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Background
In the Democratic Republic of East Timor (DRET), chloro-
quine (CQ) resistance in Plasmodium falciparum was first
reported in the 1980s [1,2]. Despite this, until 1999, CQ
plus primaquine continued to be used as the first-line
treatment of uncomplicated malaria, with sulphadoxine-
pyrimethamine (SP) as second-line, severe malaria being
treated with quinine [3].
In 1992, high levels of resistance to chloroquine were
reported [4]. In vitro and in vivo resistance to choroquine,
amodiaquine and SP was documented in the district of
Lospalos, where more than 67% treatment failure to CQ
was reported between 1999 and 2000 [3,5-8]. Conse-
quently, in early 2000, the policy for the first-line treat-
ment of uncomplicated malaria was changed. SP was
introduced for the treatment of uncomplicated falci-
parum malaria and chloroquine was used for the treat-
ment of Plasmodium vivax only. Currently, SP has been
replaced by artemether-lumefantrine for treating P. falci-
parum, but chloroquine is still the recommended treat-
ment for vivax malaria.
Genetic variation associated with both CQ and SP resist-
ance can be monitored with specific molecular markers.
The K76T mutation at the pfcrt is considered a reliable
genetic marker for CQ resistance. Polymorphisms in
pfmdr1, which encodes the P. falciparum P glycoprotein
homologue 1, modulate chloroquine resistance in mutant
pfcrt-harboring parasites in vitro [9], although their role in
vivo has not been sufficiently substantiated [10].
Molecular mechanisms of antifolate resistance in P. falci-
parum have been explored in detail [11]. Specific point
mutations in the parasite's dihydrofolate reductase (dhfr
and dihydropterate synthase (dhps) genes are associated
resistance to pyrimethamine-sulphadoxine [12-14]. The
first study of SP efficacy for the treatment of uncompli-
cated falciparum malaria, conducted in 2001, reported
81.6% single pfdhfr  108N or double C59R/S108N
mutants, but none of the isolates harboured mutations in
dhps, and the drug was confirmed to be efficacious [15].
The aim of the present study was to investigate the propor-
tions and distribution of molecular polymorphisms in the
parasite  Plasmodium falciparum dihydrofolate reductase
(pfdhfr), dihydropterate synthase (pfdhps), chloroquine
resistance transporter (pfcrt) and multi-drug resistance
(pfmdr1) genes, from samples collected four to five years
after the replacement of CQ by SP as the recommended
first-line treatment.
Methods
Study area
The Democratic Republic of East Timor (DRET) is situated
on the Eastern Part of the Island of Timor, the eastern
most of the Lesser Sunda Island (Figure 1). The study was
carried out in two different periods. The first period
(2003/2004) was carried out in two districts: (Dili and
Suai), and the second period (2004/2005) was carried out
in the former and an additional four districts: (Liquiça,
Same, Viqueque, Lospalos). These districts can be classi-
fied into three different zones, according to geographical
location: North (Dili and Liquica), South (Suai, Same and
Viqueque) and East (Lospalos).
Sample collection
Two-hundred and fifty blood samples were collected from
17 November 2003 to 7 January 2004 (period 1) and 650
from 15 December 2004 to 9 March 2005 (period 2). This
study was approved by Ministry of Health (Ref.: MS-DG/
PESQUISA-IHMT/XI/03/346 and MS/VM/PESQUISA/XII/
04) and patients gave their consent to participate. Finger-
prick blood samples were collected by passive case detec-
tion (PCD) from suspected malaria carriers presenting at
hospital/clinic, after informed consent was obtained. No
age restrictions were applied. Collected blood was used to
make thin and thick Giemsa-stained smears, which were
checked for malaria parasites by optical microscopy. A
sub-sample of the collected blood was blotted onto filter
paper for assessment of molecular markers.
Genotyping
Genomic DNA was extracted with phenol-chloroform
[16] and confirmed to include P. falciparum DNA, by use
of a species-specific PCR [17]. Each sample was then
checked for polymorphisms in three codons (51, 59 and
108) of the pfdhfr gene and two codons (437 and 540) of
the pfdhps gene, using a slight modification of the PCR-
RFLP methodology described by [18]. Polymorphisms in
two codons (75 and 76) of the pfcrt gene and two codons
(86 and 1246) of the pfmdr1 gene were detected as
described previously [19]. Digested products were sepa-
rated on 2–3% agarose gel, then stained with ethidium
bromide and visualized under UV.
Statistical analysis
A Chi-square (χ2) Test was performed to compare differ-
ences in frequency of mutant alleles among codons of the
pfcrt, pfmdr1, pfdhfr and pfdhps genes and between periods
of sampling, using SPSS 11.5 for windows, and P < 0.05
was considered significant. Association between alleles at
any two loci was tested by Fisher's Exact Test. Data from
isolates containing both alleles (polyclonal infections)
were excluded from the analysis.Malaria Journal 2009, 8:59 http://www.malariajournal.com/content/8/1/59
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Results
A total of 900 samples were checked for presence of
malaria. Mean age of sampled individuals was 21 ± 17.04
(SD) of which 51% and 49% were males and females,
respectively. Prevalence of falciparum, vivax and mixed
malaria infections as determined by optical microscopy
(OM) was underestimated in all cases, with PCR allowing
detection of a significantly higher number of cases (X2 =
15,02; p = 0,001). Thus, infection prevalence detected by
OM vs PCR, for P. falciparum, P. vivax and mixed infec-
tions, was 7.5% vs 11.4%, 3.7% vs 6.6% and 0% vs 1.0%,
respectively.
38 of the 250 and 74 of the 650 patients were infected by
P. falciparum in period 1 and period 2, respectively, as
determined by PCR. Results of Single Nucleotide Poly-
morphism (SNP) typing are summarized in Table 1. Over
97% of the samples inspected showed the CQ resistance
pfcrt 76 core mutation and of these, 38 and 56% had the
additional pfmdr1 86Y mutation in the first and second
periods respectively. The 75E polymorphism was also
observed in 12.5% of isolates from period 2. No mutant
alleles at codon pfmdr1 1246 were detected.
More than 97% of the parasite population inspected
exhibited the pfdhfr core mutation 108N, and an increase
in mutant alleles from the first to second period in two
others loci examined (pfdhfr51 and pfdhfr  59) was
detected. All isolates presented the Pfdhfr 108N mutation
in combination with dhfr 51I and/or dhfr 59R. In particu-
lar, the pfdhfr triple mutation was seen in the great major-
ity of samples (Table 1). There was a significant difference
(X2 = 31.1; p = 0.001) in the prevalence of the pfdhps 437G
mutation which increased from 60% to 100% from the
first to second periods, respectively. The quadruple muta-
tion [triple dhfr (51I, 59R and 108N) + dhps 437G ] was
found in 82.3% of isolates. None of the samples con-
tained quintuple mutations. There was no significant
association between any particular genotype prevalence
and patient age or sex.
Map of the Democratic Republic of East Timor showing locations of the districts surveyed Figure 1
Map of the Democratic Republic of East Timor showing locations of the districts surveyed.Malaria Journal 2009, 8:59 http://www.malariajournal.com/content/8/1/59
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Table 1: Frequency (%) of the Pfdhfr (codons 51, 59 and 108), Pfdhps (codons 437 and 540), Pfcrt (codons 76 and 75), Pdmdr1 (codons 86 
and 1246) genotypes and multiple mutations in first and second assay periods.
Period 1
(2003–2004)
Period 2
(2004–2005)
Gene Codon (N = 38) (%) (N = 74) (%)
Pfcrt 75
(wild-type) N 16 100 27 56
( M u t a n t )  E 006 1 3
N + E 0 0 15 31
Not determined 22 22
76
( w i l d - t y p e )  K 1300
( M u t a n t )  T 3 29 75 9 1 0 0
K  +  T 0000
Not determined 5 15
Pfmdr1 86
(wild-type) N 8 24 18 27
( M u t a n t )  Y 1 33 83 75 6
N  +  Y 1 33 81 11 7
Not determined 4 8
1246
(wild-type) D 32 100 64 97
( M u t a n t )  Y 0000
D  +  Y 0023
Not determined 6 8
Pfdhfr 51
(wild-type) N 9 24 8 11
( M u t a n t )  I 2 56 66 68 9
N + I 4 10 0 0
Not determined 0 0
59
(wild-type) C 11 29 9 14
( M u t a n t )  R 2 46 35 38 4
C  +  R 3812
Not determined 0 11
108
( w i l d - t y p e )  S 0023
(Mutant) N 28 100 62 97
S  +  N 0000
Not determined 10 10
Pfdhps 437
(wild-type) A 14 40 0 0
( M u t a n t )  G 2 16 06 7 1 0 0
A  +  G 0000
Not determined 3 7
540
(wild-type) K 34 97 67 100
( M u t a n t )  E 1300
K  +  E 0000
Not determined 3 7
Multiple mutations
dhfr 51I+108N 19 68 60 97
dhfr 59R+108N 17 61 52 84
d h f r  5 1 I  + 5 9 R + 1 0 8 N 1 65 75 38 6
dhfr 51I +59R+108N+dhps 437G 13 46 51 82Malaria Journal 2009, 8:59 http://www.malariajournal.com/content/8/1/59
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Potential associations between alleles at different loci
were evaluated, except for those whose prevalence was
found to be fixed, or near fixation. Consequently, a non-
random association was observed between the pfdhfr and
pfdhps genes in the group of isolates collected during the
first survey (2003/2004). Here, concomitant significant
occurrence of wild-type/wild-type or mutant/mutant
pfdhfr51/pfdhps 437 alleles were observed among 29 out
of 31 samples, whilst pfdhfr 59/pfdhps 437 occurred in 25
of the 33 cases successfully genotyped (Table 2).
Discussion
The present study evaluated mutation prevalence in the
Pfcrt, Pfmdr1, Pfdhfr and Pfdhps genes among natural par-
asite populations of East Timor. Overall, the frequency of
mutant alleles progressively increased from the first to sec-
ond period, including those suggested to be involved in
chloroquine resistance. These data is in contrast with pre-
vious studies where the frequency of the Pfcrt 76T muta-
tion decreased progressively with abolition of
chloroquine for treatment for P. falciparum malaria
[20,21]. The explanation for the persistence of the K76T
mutation in East Timor P. falciparum populations may
entail several factors. First, despite the discontinuation of
CQ, the drug was still recommended for vivax malaria
infections. Vivax malaria accounts for 20 – 40% of all
malaria cases [7]. Furthermore, there is the problem of
underestimation of mixed infections, as the diagnosis of
malaria species in East Timor is made by conventional
microscopy alone. Second, anti-malarial drugs are still
widely available commercially in East Timor and most
people use drugs acquired from parallel markets. The
indiscriminate or inappropriate use and unsupervised
drugs use for malaria infections is likely to be implicated
in the maintenance of CQ-resistant parasites. Third, wide-
spread use of quinine and amodiaquine in East Timor,
which have been associated to certain extent to pfcrt 76T
and pfmdr1 86Y mutations [22,23], may impose positive
selection, maintaining CQ resistance. Fourth, there has
been extensive population movement between East Timor
and West Timor-Indonesia, where malaria is highly
endemic and CQ resistance levels are high. Thus, dissem-
ination of resistant genotypes is likely to play an impor-
tant role in maintaining CQ resistance in the region. Last,
the reduced genetic diversity and lower recombination
rates in south-east Asian parasites (when compared to
Africa) may help maintain predominant genotypes even if
mutations carry a fitness cost.
Point mutations in pfmdr1 N86Y and D1246Y, occasion-
ally cited as potential contributors to chloroquine resist-
ance [24] were also inspected. The pfmdr1 86Y allele was
slightly predominant (56% prevalence) as previously
observed both in Africa [25] and in some regions in Indo-
nesia [26].
Since SP replaced CQ as recommended first line drug, the
putative efficacy of SP was inferred by inspecting muta-
tions in key codons of P. falciparum dhfr and dhps genes.
Results indicated that mutation prevalence in those genes
have increased steadily over a short period of time in con-
trast to an earlier study by [15]. Additionally, all isolates
exhibited the pfdhfr 108N mutation in combination with
dhfr  51I and/or dhfr  59R mutations, indicative of
increased levels of pyrimethamine resistance [24,27-29].
Also, triple mutants in the Pfdhfr gene (51I+59R+108N)
accounted for 85.5% of all isolates further re-enforcing
that high levels of pyrimethamine resistance are present
[27,30].
The most common mutations polymorphism in the
pfdhps gene was the 437G; only one case presented a 540E
mutation. These observations are consistent with pfdhps
437G being the first to emerge as result of pressure by sul-
pha drugs [11,31,32], which confers resistance to sul-
phadoxine in P. falciparum [17,33,34]. It was also verified
that a high number isolates (82.3%) carried 4 mutations
distributed among the dhfr and dhps genes {quadruple
mutation: (51I + 59R + 108N + 437G)}, a pattern inferred
in the presence of high levels of resistance to the
pyrimethamine and in some cases, clinical resistance to SP
[35].
Pfdhfr is present in chromosome 4 and pfdhps lies present
in chromosome 8 of P. falciparum. Thus, both genes are
physically distant and in conditions of normal transmis-
sion any particular haplotypes of each gene should be
found randomly in human hosts. However, the present
data highlights that resistance-associated alleles encoding
both the pfdhfr  51 and 59 mutants are non-randomly
associated with pfdhps 437 mutants, therefore indicating
that both loci are under strong directional selection by
Table 2: Significant associations between different alleles of the Pfdhfr e Pfdhps genes.
Codons Genotype Number observed Fisher's Exact Test (2-sided)
(P- value)
51 × 437 (N = 31) N-A (wild-type) 8 P = 0.001 < 0.05
I-G (mutant) 21
59 × 437 (N = 33) C-A (wild-type) 7 P = 0.001 < 0.05
R-G (mutant) 18Malaria Journal 2009, 8:59 http://www.malariajournal.com/content/8/1/59
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sulphadoxine-pyrimethamine (SP), suggestive of selective
advantage conferred by the presence of the two resistant
alleles.
Conclusion
This work suggests that SP resistance may already exist in
the East Timor, and that the continuous use of the drug
will contribute to higher patterns of inefficacy in the treat-
ment of falciparum malaria. Nevertheless, these findings
could be complemented with in vivo data as to reflect
more closely the therapeutic efficacy of CQ and SP pat-
terns in the epidemiological scenario. Persistence of CQ-
resistant mutants even after supposed drug withdrawal re-
enforces the need of its use against P. vivax exclusively. The
association between pfdhfr51/pfdhps437 and pfdhfr  59/
pfdhps 437 alleles indicates that these are undergoing con-
comitant positive selection.
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